Statistical considerations on design and analysis of bridging and multiregional clinical trials

Yi Tsong¹

Affiliations

Yi Tsong. J Biopharm Stat. 2012 Sep.

. 2012 Sep;22(5):1078-80.

doi: 10.1080/10543406.2012.702652.

Yi Tsong¹

¹ Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, USA. yi.tsong@fda.hhs.gov

No abstract available

Similar articles

Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials.
Tsong Y, Wang W. Tsong Y, et al. J Biopharm Stat. 2012 Sep;22(5):875-8. doi: 10.1080/10543406.2012.702650. J Biopharm Stat. 2012. PMID: 22946936 No abstract available.
Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
Chen CT, Hung HM, Hsiao CF. Chen CT, et al. J Biopharm Stat. 2012 Sep;22(5):1037-50. doi: 10.1080/10543406.2012.701585. J Biopharm Stat. 2012. PMID: 22946948 Review.
Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
Tsou HH, Tsong Y, Chang WJ, Dong X, Hsiao CF. Tsou HH, et al. J Biopharm Stat. 2012 Sep;22(5):1051-9. doi: 10.1080/10543406.2012.701586. J Biopharm Stat. 2012. PMID: 22946949 Review.
Qualitative consistency of treatment effects in multiregional clinical trials.
Tanaka Y, Li G, Wang Y, Chen J. Tanaka Y, et al. J Biopharm Stat. 2012 Sep;22(5):988-1000. doi: 10.1080/10543406.2012.703603. J Biopharm Stat. 2012. PMID: 22946945 Review.
Sample size allocation to regions in a multiregional trial.
Uesaka H. Uesaka H. J Biopharm Stat. 2009 Jul;19(4):580-94. doi: 10.1080/10543400902963185. J Biopharm Stat. 2009. PMID: 20183427

Bridging across patient subgroups in phase I oncology trials that incorporate animal data.
Zheng H, Hampson LV, Jaki T. Zheng H, et al. Stat Methods Med Res. 2021 Apr;30(4):1057-1071. doi: 10.1177/0962280220986580. Epub 2021 Jan 27. Stat Methods Med Res. 2021. PMID: 33501882 Free PMC article.